1Suppliers
1Customers
2Debt Items
20Related Chains

Forte Biosciences, Inc. Suppliers

TickerNameConfidenceEvidence
CLINICAL-RESEARCH-ORGANIZATION CLINICAL-RESEARCH-ORGANIZATION 92% The Company entered into agreements with a clinical research organization ("CRO") for clinical trials of FB102, its product candidate.

Forte Biosciences, Inc. Customers

TickerNameConfidenceEvidence
ARGENX-BV ARGENX-BV 90% As part of the Offering, argenx BV has made a strategic investment in the Company.

Forte Biosciences, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
FBRX-DEBT-9444 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-31.
FBRX-DEBT-9443 Warrants outstanding: 479000 90% xbrl warrant detail from xbrl 2025-06-30.

Forte Biosciences, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Forte Biosciences, Inc..

Forte Biosciences, Inc. Ownership

HolderNameConfidenceEvidence
FBRX-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 70 tracked holders.

Forte Biosciences, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
ATOS Atossa Therapeutics, Inc. 100.00 2
CALC CalciMedica, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
GRDX GridAI Technologies Corp. 100.00 2